Piqray (Alpelisib)

Save over 80% on Piqray - called Pivikto from Europe- manufactured in Europe and shipped from India.

Manufacturer of Pivikto: Novartis Pharma Stein AG. Postfach Stein SWITZERLAND. Schaffhauserstrasse CH-4332 Stein. Switzerland

Information about Piqray (Alpelisib)

Piqray is a prescription medication that contains alpelisib as its active ingredient. It is used to treat certain types of breast cancer, specifically those that are HR-positive (hormone receptor-positive) and HER2-negative (human epidermal growth factor receptor 2-negative), with a specific mutation (PIK3CA). It works by inhibiting a protein involved in cancer cell growth and proliferation, helping to slow down or stop the spread of cancer cells.

Product Highlights

• Piqray is used to treat advanced or metastatic breast cancer that is HR-positive, HER2-negative, and has a PIK3CA mutation. It is used in combination with an aromatase inhibitor for patients who have not received prior treatment for advanced breast cancer.
• This mutation is present in a subset of patients with breast cancer, and Piqray targets the specific signaling pathway associated with this mutation.

Key Ingredient

• Alpelisib

Key Benefits

• Alpelisib specifically targets cancer cells with a PIK3CA mutation, offering a more focused approach to treating breast cancer.
• When combined with an aromatase inhibitor, Piqray provides an effective option for treating advanced breast cancer in women with specific genetic mutations.
• Alpelisib works by slowing the growth and spread of cancer cells, which may help extend survival in patients with advanced or metastatic breast cancer.
• Piqray is taken as a tablet once daily, providing a convenient treatment option for patients.

Direction of Use

• The recommended dose of Piqray is typically 300 mg once daily, taken with food, in combination with an aromatase inhibitor like letrozole. Dosage may vary depending on individual patient needs, and adjustments may be necessary based on side effects or other health factors.
• The tablet should be swallowed whole with food. It should not be crushed or chewed.
• If you forget a dose, take it as soon as you can, unless it's nearly time for your next dose. Do not take a double dose to compensate for a missed one.

Safety Concerns

• Common side effects may consist of diarrhea, nausea, tiredness, loss of appetite, and skin rashes.
• Serious side effects can include high blood sugar (hyperglycemia), severe skin reactions, liver problems, and severe diarrhea. Monitoring for these side effects is necessary.
• Patients taking Piqray should have their blood sugar levels monitored regularly due to the risk of hyperglycemia.
• Liver enzymes should be monitored during treatment to detect any liver-related issues early.
• Patients may be more susceptible to infections due to changes in immune system function.

Avoid Piqray (Alpelisib) If

• Do not use Piqray if you are allergic to alpelisib or any of its components.
• Patients with uncontrolled diabetes or high blood sugar (hyperglycemia) should avoid Piqray or use it with caution under close medical supervision.
• If you have severe liver impairment, Piqray may not be recommended.
• Piqray can harm a developing fetus, so it should not be used during pregnancy. Women should use effective contraception during treatment with Piqray and for some time after finishing the treatment.
• It is unclear whether Piqray passes into breast milk, so breastfeeding is not recommended during treatment with this medication.